Inhibition of the serine proteases of the complement system. 2013

Péter Gál, and József Dobó, and László Beinrohr, and Gábor Pál, and Péter Závodszky
Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary. gal@enzim.hu

Proteases play important roles in human physiology and pathology. The complement system is a proteolytic cascade, where serine proteases activate each other by limited proteolysis in a strictly ordered manner. Serine proteases are essential in both the initiation and the amplification of the cascade. Since uncontrolled complement activation contributes to the development of serious disease conditions, inhibition of the complement serine proteases could be an attractive therapeutic approach. In this chapter, we give a brief overview of the major types of natural serine protease inhibitors and their role in controlling the complement cascade. A special emphasis is laid on C1-inhibitor, a natural complement protease inhibitor, which is approved for clinical use in hereditary angioedema (HAE). We also examine the potential of developing artificial complement protease inhibitors. Synthetic small-molecule drugs can be very efficient serine protease inhibitors, but they usually lack sufficient specificity. A promising approach to yield more specific compounds is the alteration of natural protease inhibitors through engineering or directed evolution resulting in new variants with fine-tuned specificity and enhanced affinity.

UI MeSH Term Description Entries
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015202 Protein Engineering Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes. Genetic Engineering of Proteins,Genetic Engineering, Protein,Proteins, Genetic Engineering,Engineering, Protein,Engineering, Protein Genetic,Protein Genetic Engineering
D015842 Serine Proteinase Inhibitors Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. Serine Endopeptidase Inhibitor,Serine Endopeptidase Inhibitors,Serine Protease Inhibitor,Serine Protease Inhibitors,Serine Proteinase Antagonist,Serine Proteinase Antagonists,Serine Proteinase Inhibitor,Serine Proteinase Inhibitors, Endogenous,Serine Proteinase Inhibitors, Exogenous,Serine Protease Inhibitors, Endogenous,Serine Protease Inhibitors, Exogenous,Antagonist, Serine Proteinase,Endopeptidase Inhibitor, Serine,Inhibitor, Serine Endopeptidase,Inhibitor, Serine Protease,Inhibitor, Serine Proteinase,Protease Inhibitor, Serine,Proteinase Antagonist, Serine,Proteinase Inhibitor, Serine
D050718 Complement C1 Inhibitor Protein An endogenous 105-kDa plasma glycoprotein produced primarily by the LIVER and MONOCYTES. It inhibits a broad spectrum of proteases, including the COMPLEMENT C1R and the COMPLEMENT C1S proteases of the CLASSICAL COMPLEMENT PATHWAY, and the MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES. C1-INH-deficient individuals suffer from HEREDITARY ANGIOEDEMA TYPES I AND II. C1 Esterase Inhibitor,C1-INH Protein,C1-Inhibitor Protein,Complement C1-Inhibitor Protein,Plasma Protease C1 Inhibitor,SERPING1,Serpin Family G Member 1,Serpin G1,C1 INH Protein,C1 Inhibitor Protein,Esterase Inhibitor, C1
D054852 Small Molecule Libraries Large collections of small molecules (molecular weight about 600 or less), of similar or diverse nature which are used for high-throughput screening analysis of the gene function, protein interaction, cellular processing, biochemical pathways, or other chemical interactions. It includes virtual libraries. Chemical Libraries,Molecular Libraries, Small,Libraries, Chemical,Libraries, Small Molecular,Libraries, Small Molecule,Molecule Libraries, Small,Small Molecular Libraries
D057057 Serine Proteases Peptide hydrolases that contain at the active site a SERINE residue involved in catalysis. Serine Proteinases,Serine Protease,Serine Protein Hydrolases,Serine Proteinase,Protease, Serine,Proteases, Serine,Protein Hydrolases, Serine,Proteinase, Serine,Proteinases, Serine

Related Publications

Péter Gál, and József Dobó, and László Beinrohr, and Gábor Pál, and Péter Závodszky
October 2000, Biochemical Society transactions,
Péter Gál, and József Dobó, and László Beinrohr, and Gábor Pál, and Péter Závodszky
January 1998, Advances in immunology,
Péter Gál, and József Dobó, and László Beinrohr, and Gábor Pál, and Péter Závodszky
November 1981, FEBS letters,
Péter Gál, and József Dobó, and László Beinrohr, and Gábor Pál, and Péter Závodszky
June 2012, Current opinion in structural biology,
Péter Gál, and József Dobó, and László Beinrohr, and Gábor Pál, and Péter Závodszky
January 1981, Methods in enzymology,
Péter Gál, and József Dobó, and László Beinrohr, and Gábor Pál, and Péter Závodszky
February 2004, Biochemical Society transactions,
Péter Gál, and József Dobó, and László Beinrohr, and Gábor Pál, and Péter Závodszky
January 1983, Seikagaku. The Journal of Japanese Biochemical Society,
Péter Gál, and József Dobó, and László Beinrohr, and Gábor Pál, and Péter Závodszky
April 2001, Cellular and molecular life sciences : CMLS,
Péter Gál, and József Dobó, and László Beinrohr, and Gábor Pál, and Péter Závodszky
July 1992, Journal of immunology (Baltimore, Md. : 1950),
Péter Gál, and József Dobó, and László Beinrohr, and Gábor Pál, and Péter Závodszky
September 1982, Biochemical pharmacology,
Copied contents to your clipboard!